市场调查报告书
商品编码
1494619
基因组测试市场:按组件、技术、应用、分销管道、最终用途划分 - 2024-2030 年全球预测Genome Testing Market by Component (Consumables, Equipment, Software & Services), Technology (Microarrays, Next-Generation Sequencing, Targeted Sequencing), Application, Distribution Channel, End-use - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年基因组检测市场规模为175.7亿美元,预计2024年将达到197.6亿美元,2030年将达419亿美元,复合年增长率为13.21%。
基因组测试通常称为全基因组定序 (WGS),涉及一次性检查生物体基因组中 DNA 的完整序列。这种全面的分析涵盖了所有类型的遗传变异,包括插入、缺失、单核苷酸多态性 (SNP)、拷贝数变异和大的结构变化。人们对早期疾病检测和预防的日益关注,以及对血统和系谱日益增长的兴趣,也增加了基因组测试的重要性。然而,与基因组设备相关的高成本和解释遗传讯息的复杂性正在影响市场成长。此外,人工智慧和巨量资料分析的结合以改善遗传资料的解释,正在为市场成长创造潜在机会。
主要市场统计 | |
---|---|
基准年[2023] | 175.7亿美元 |
预计年份 [2024] | 197.6亿美元 |
预测年份 [2030] | 419亿美元 |
复合年增长率(%) | 13.21% |
区域洞察
在美洲,特别是在美国和加拿大,个人化医疗意识的增强以及对预防性医疗保健的兴趣日益浓厚,正在推动消费者对基因组检测的需求。在高可支配收入和大量医疗保健支出的推动下,这些地区的客户表现出投资健康和保健的意愿。遗传疾病的日益普及正在推动对基因组检测服务的需求。由于成员国之间医疗保健系统、法规和消费者态度的差异,欧盟 (EU) 为基因组检测提供了多元化的市场。隐私权问题、道德考量以及一般资料保护规范 (GDPR) 等法规结构对客户的购买行为有重大影响。中东和非洲新兴国家对基因组检测的需求程度不同。在中东,每个国家都拥有发达的医疗保健系统,人们对个人化医疗的基因组测试的兴趣与日俱增。亚太地区基因组检测市场正在迅速开拓,特别是在中国、日本和印度。中国对生物技术的投资正在迅速增加,大型基因组研究计划和国际合作就是证明。
FPNV定位矩阵
FPNV定位矩阵对于评估基因组检测市场供应商的市场定位至关重要。此矩阵提供了对供应商的全面评估,并检验了与商务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可对基因组测试市场中供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献,您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外,该分析还提供了对该领域竞争性质的宝贵见解,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对目前在基因组测试市场中的地位进行全面评估,使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[199 Pages Report] The Genome Testing Market size was estimated at USD 17.57 billion in 2023 and expected to reach USD 19.76 billion in 2024, at a CAGR 13.21% to reach USD 41.90 billion by 2030.
Genome Testing, often referred to as whole genome sequencing (WGS), involves examining the complete sequence of DNA in an organism's genome at a single time. This comprehensive analysis covers all types of genetic variations, including insertions, deletions, single nucleotide polymorphisms (SNPs), copy number variations, and large structural changes. Growing emphasis on early disease detection & prevention, along with the increasing interest in ancestry and genealogy, boosts the significance of genome testing. However, the high cost associated with genomics equipment and the complexity of interpreting genetic information impact the market growth. Furthermore, the integration of AI and big data analytics for improved interpretation of genetic data is creating a potential opportunity for market growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 17.57 billion |
Estimated Year [2024] | USD 19.76 billion |
Forecast Year [2030] | USD 41.90 billion |
CAGR (%) | 13.21% |
Regional Insights
In the Americas, particularly in the United States and Canada, the consumer need for genome testing is driven by a heightened awareness of personalized medication and a growing focus on preventive healthcare procedures. Customers in these regions exhibit a willingness to invest in health and wellness, supported by higher disposable income and substantial healthcare spending. The increasing prevalence of genetic disorders has catalyzed the demand for genome testing services. The European Union displays a diverse market for genome testing due to differences in healthcare systems, regulations, and consumer attitudes across member countries. Privacy concerns, ethical considerations, and regulatory frameworks such as the General Data Protection Regulation (GDPR) profoundly influence customer purchasing behavior. Emerging economies in the MEA show varying levels of demand for genome testing. The Middle East, with its well-funded healthcare systems in countries, is witnessing an increased interest in genome testing for personalized medicine. The Asia Pacific region, especially China, Japan, and India, exhibits a rapidly developing market for genome testing. China's investment in biotechnology has soared, as evidenced by its large-scale genome research projects and international collaborations.
Market Insights
The market dynamics represent an ever-changing landscape of the Genome Testing Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Genome Testing Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Genome Testing Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Cone Health Readies for 100,000 Person Genomics Project
Cone Health is on the brink of launching an expansive genomic testing initiative designed to enhance the health and longevity of individuals throughout the Piedmont Triad region. The program aims to harness the predictive power of genomics to identify individuals at risk for certain diseases, such as breast cancer and cardiac issues, thereby enabling early intervention and personalized healthcare. Cone Health has partnered with population genomics specialist, Helix, and envisages recruiting 100,000 healthy volunteers within five years for DNA sequencing via blood or saliva samples. [Published On: 2023-12-04]
Illumina Launches Advanced Liquid Biopsy Assay to Enable Comprehensive Genomic Profiling of Solid Tumors
Illumina Inc. has unveiled its latest innovation, the TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2), designed for the comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) using a noninvasive liquid biopsy approach. The TSO 500 ctDNA v2 presents a significant advancement for cancer research, offering a viable solution for genomic profiling when tissue samples are unattainable or enhancing the insights gained from traditional tissue-based tests. [Published On: 2023-11-01]
Apollo Opens Genomic Institute In Chennai, to Open Three More in 2023
Apollo Hospitals Group has inaugurated a Genomics Institute in Chennai to advance the study of genes and tackle genetic disorders. This marks the newest addition to their growing network with existing facilities in Mumbai and Delhi. By the end of 2023, Apollo is poised to enhance its genomic footprint with additional institutes launching in Hyderabad, Bangalore, and Ahmedabad. The Chennai Institute is set to offer comprehensive genomic services, including genetic evaluation, clinical diagnostics, obstetric genetics, and cancer genomics. These services are meticulously designed to provide patients with critical information for the management and prevention of genetic disorders. [Published On: 2023-04-25]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Genome Testing Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Genome Testing Market, highlighting leading vendors and their innovative profiles. These include 10x Genomics, 23andMe, Inc, Abbott Laboratories, Agilent Technologies, Inc., BGI Group, Bio-Rad Laboratories, Inc., Danaher Corporation, Eurofins Scientific SE, F. Hoffmann-La Roche, Ltd., Freenome Holdings, Inc., GeneDx, LLC, Genomic Testing Cooperative, Helix OpCo, LLC, Illumina, Inc., Merck KGaA, New England Biolabs, Inc., Novogene Co, Ltd., Oxford Nanopore Technologies PLC, PerkinElmer Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Takara Bio Inc, Thermo Fisher Scientific Inc., Ultima Genomics, Inc., and VWR International, LLC.
Market Segmentation & Coverage